Logo Image
|Articles|July 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-07-01-2001
  • Volume 0
  • Issue 0

Generic Threat

Author(s)Kevin Gopal

Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.

Articles in this issue

over 25 years ago

Pharmacies: OTC Price Wars

over 25 years ago

One Disease at a Time

over 25 years ago

Overview of the Industry: A World of Opportunities

over 25 years ago

The Power Shift

over 25 years ago

A Giant Stumbles

over 25 years ago

Overruled: No More Dual Pricing

over 25 years ago

Submerged

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more